Jesus C Fabregas

Jesus C Fabregas, MD, MPH, FACP


Business Phone: (352) 273-7832
Business Email:

About Jesus C Fabregas

Jesus C. Fabregas, MD, MPH, FACP is an Assistant Professor of Medicine in the Division of Hematology & Oncology at the University of Florida College of Medicine.

Dr. Fabregas received his medical degree from Universidad Del Norte in Colombia. Following medical school, he completed his internship and residency in Internal Medicine at the University of Miami, Miller School of Medicine in Miami, Florida, where he earned the American College of Physicians Outstanding Resident Award. He then finished a post-doctorate fellowship in hematology and oncology at Sylvester Cancer Center – University of Miami.

Dr. Fabregas most recently completed his Master of Public Health degree in Epidemiology from Harvard University – Harvard TH Chan School of Public Health. As part of his public health efforts, his research evaluated inequities and the impact of social determinants of health in cancer care in the US.

At UF Health, Dr. Fabregas will take care of patients with gastrointestinal malignancies, with a special interest in colon and rectal cancer, using a multi-disciplinary approach. He aims to improve patient’s quality of life and to provide personalized care by accessing the latest targeted and immunotherapy treatments through clinical trials.

His recent research endeavors included a meta-analysis studying the feasibility of minimizing toxicities in patients with early rectal cancer, and refining prognosis and treatment selection for patients with early colon cancer applying a machine-learning model. He has presented the results of his research in several oncology society meetings including American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and European Society of Medical Oncology – GI (ESMO-GI).

He is board certified in Medical Oncology, Hematology and Internal Medicine with the American Board of Internal Medicine. He is a member of the American Society of Clinical Oncology and a Fellow of the American College of Physicians.

In addition to his passion about oncology, Dr. Fabregas enjoys spending time with his family, hiking, traveling and exploring the outdoors.


Peter A. Cassileth, M.D. Award
2015 · University of Miami Miller School of Medicine
Outstanding Resident Award
2012 · American College of Physicians
National Winner – Poster Presentation
2011 · ACP Internal Medicine Meeting
1st Place Oral Presentation
2010 · ACP Scientific Meeting

Board Certifications

  • Hematology
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine
  • Medical Oncology
    American Board of Internal Medicine

Clinical Profile

  • Medicine
  • Gastroenterology
  • Oncology
Areas of Interest
  • Cancer – resources
  • Cancer treatment information
  • Colon cancer screening
  • Colorectal cancer
  • Colorectal cancer – resources
  • Gastrointestinal disorders – resources
  • Rectal bleeding

Research Profile

Open Researcher and Contributor ID (ORCID)


Areas of Interest
  • Association between Socioeconomic Determinants of Health
  • Clinical trials in gastrointestinal malignancies – colorectal, pancreas, esophagogastric, hepatobiliary, neuroendocrine tumors.
  • Disparities in cancer outcomes
  • Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision
  • Epidemiology and public health
  • Immunotherapy
  • Impact of Medicaid Expansion Status and Race on a Late Diagnosis of Melanoma
  • Minimizing toxicities in patients with early rectal cancer
  • Personalized medicine, next generation sequencing
  • Quality of life
  • Refining prognosis and treatment selection for patients with early colon cancer


Impact of Medicaid Expansion Status and Race on Metastatic Disease at Diagnosis in Patients with Melanoma.
Journal of racial and ethnic health disparities. [DOI] 10.1007/s40615-021-01166-6. [PMID] 34648145.
The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma.
Oncotarget. 12(15):1490-1498 [DOI] 10.18632/oncotarget.28025. [PMID] 34316329.
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
American journal of hematology. 90(9):778-83 [DOI] 10.1002/ajh.24082. [PMID] 26044261.
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
Leukemia & lymphoma. 56(6):1750-5 [DOI] 10.3109/10428194.2014.975801. [PMID] 25315074.
Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer.
Expert review of anticancer therapy. 13(9):1065-72 [DOI] 10.1586/14737140.2013.829639. [PMID] 24053205.
Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.
Journal of translational medicine. 11 [DOI] 10.1186/1479-5876-11-62. [PMID] 23497415.
Patient with synchronous low grade leiomyosarcoma of the thigh, primary pancreatic neuroendocrine tumor, and lung metastases: Why biopsy of metastases should be the standard.
Journal of gastrointestinal oncology. 2(2):109-12 [DOI] 10.3978/j.issn.2078-6891.2011.008. [PMID] 22811838.


Master of Public Health in Epidemiology
2019-2021 · Harvard University
Post-Doctoral Fellowship in Hematology and Oncology
2012-2015 · University of Miami Miller School of Medicine
Residency in Internal Medicine
2009-2012 · University of Miami Miller School of Medicine
Medical Degree
1998-2003 · University of the North

Contact Details

(352) 273-7832
Business Mailing:
PO Box 100278